Introduction/Objective:Several nutraceuticals, food, and cosmetic products can be developed using
royal jelly. It is known for its potential health benefits, including its ability to boost the immune system and reduce
inflammation. It is rich in vitamins, minerals, and antioxidants, which can improve general health. Royal
jelly (RJ) is also being studied as a potential therapeutic agent for cancer and other chronic diseases. It is effective
in reducing tumor growth and stimulating immunity.Methods:In this study, we investigated the effects of royal jelly on cancerous A549 cells and healthy MRC-5
cells at various doses ranging from 1.25 to 10 mg/ml. Royal jelly's anti-proliferative effect was evaluated by MTT
and SRB assay for 48 h. The induction of necrosis and apoptosis was assessed by flow cytometry as well. The
relative amounts of major molecules in Royal jelly were determined by FTIR spectroscopy to identify key functional
groups and molecular structures. In addition, this technique was used for the first time to detect changes in
the macromolecular composition of lung cells treated with royal jelly. Thus, it provided insights into the relative
abundance of proteins, lipids, and carbohydrates, which could correlate with their bioactive properties.Results:The antiproliferative effect of Royal jelly was found to be selective on A549 cells in a dose-dependent
manner with an IC50 of 9.26 mg/mL, with no cytotoxic effects on normal MRC-5 cells. Moreover, Royal jelly
induced predominantly necrotic cell death in A549 cells, %39.10 at 4 mg/ml and %57.88 at 10 mg/ml concentrations.
However, the necrosis rate in MRC-5 cells was quite low, at 9.16% and 20.44% at the same doses. Royal
jelly showed dose-dependent selective cytotoxicity toward A549 cells, whereas it exhibited no apparent cytotoxicity
in MRC-5 cells. In order to identify the biomolecular changes induced by royal jelly, we used two unsupervised
chemometric pattern recognition algorithms (PCA and HCA) on the preprocessed sample FTIR spectra to
determine the effects of royal jelly on cell biochemistry. According to PCA and HCA results, RJ treatments especially
affected biomolecules in A549 cells. The total spectral band variances in the PCA loading spectra were
calculated for understanding biomolecular alterations. These plots revealed profound changes in the lipid, protein,
and nucleic acid content of RJ-applied lung cells, primarily identifying RJ and H2O2 treated groups for A549
cells.Conclusion:Ultimately, the selective cytotoxicity of royal jelly toward A549 cancerous cells suggests that royal
jelly may be a promising therapeutic agent for identifying innovative lung cancer treatment strategies. Additionally,
understanding the molecular alterations induced by royal jelly could guide the development of novel cancer
treatments that exploit its bioactive properties. This could lead to more effective and safer therapies.